<DOC>
	<DOCNO>NCT02149524</DOCNO>
	<brief_summary>A Phase III Randomised , Double-Blind , Parallel Group , Multicentre Study Compare Efficacy , Safety , Pharmacokinetics Immunogenicity SB3 ( propose trastuzumab biosimilar ) Herceptin® Women Newly Diagnosed HER2 Positive Early Locally Advanced Breast Cancer Neoadjuvant Setting</brief_summary>
	<brief_title>A Study Compare Effect SB3 Herceptin® Women With HER2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female age 1865 year Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Nonmetastatic , unilateral newly diagnose primary breast cancer clinical stage II III include inflammatory breast cancer : 1. tumour size ≥ 2 cm 2. histologically confirm primary invasive carcinoma breast 3 . HER2positivity confirm central laboratory accredit local laboratory define immunohistochemistry ( IHC ) 3+ fluorescence situ hybridisation ( FISH ) + Known hormone receptor ( oestrogen receptor progesterone receptor ) status Baseline leave ventricular ejection fraction ( LVEF ) ≥ 55 % measure echocardiography multiple gated acquisition ( MUGA ) scan Subjects must able provide inform consent , must obtain prior study related procedure Metastatic ( stage IV ) bilateral multifocal/multicentric breast cancer History prior invasive breast carcinoma , except subject past history ductal carcinoma situ ( DCIS ) and/or lobular carcinoma situ ( LCIS ) treat surgery Past current history malignant neoplasm within 5 year prior Randomisation , except curatively treat carcinoma situ uterine cervix , basal cell carcinoma skin squamous cell carcinoma skin ( malignant neoplasm occur 5 year prior Randomisation permit curatively treat surgery ) Previous history radiation therapy , immunotherapy , chemotherapy biotherapy ( include prior HER2 direct therapy ) Major surgery within 4 week prior Randomisation minor surgery within 2 week prior Randomisation ( major surgery define surgery require general anaesthesia ) Serious cardiac illness would preclude use trastuzumab : 1. history document congestive heart failure ( CHF ) ( New York Heart Association , NYHA , class II great heart disease ) 2 . LVEF &lt; 55 % echocardiography MUGA scan 3. angina pectoris require antianginal medication 4. evidence transmural infarction electrocardiogram ( ECG ) 5. uncontrolled hypertension ( systolic &gt; 180 mmHg and/or diastolic &gt; 100 mmHg ) 6. clinically significant valvular heart disease 7. high risk uncontrolled arrhythmias Serious pulmonary illness enough cause dyspnoea rest require supplementary oxygen therapy Known history hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) infection Other concurrent serious illness may interfere plan therapy include severe cardiovascular , pulmonary , metabolic infectious condition Known hypersensitivity investigational product ( IPs ) , nonIPs ingredient excipients IPs nonIPs Known hypersensitivity murine proteins Known history dihydropyrimidine dehydrogenase ( DPD ) deficiency Preexisting peripheral sensory motor neuropathy ≥ grade 2 , define National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) v4.0 Pregnant lactate woman . A pregnancy test result require woman childbearing potential include woman menopause onset within 2 year prior Randomisation . Women childbearing potential must agree use contraceptive method ( see section 7.4.2 ) study 6 month last dose IP Concurrent hormonal therapy include birth control pill , ovarian hormone replacement menopause , selective oestrogen receptor modulator ( SERM ) either osteoporosis breast cancer prevention Subjects unwilling follow study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HER2 Positive Breast Cancer</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Biosimilar</keyword>
</DOC>